At enkelte velger å selge i dag, er utenfor min fatteevne😳
2 Likes
Jah… 24mnd data skal vel teknisk sett kunne leses ut/ meldes tidlig neste uke og på mandag er vel børsen kanskje stengt? Kan bli en hyggelig åpning på tirsdag såfall
4 Likes
Får nok en fin opptur til 9.50-10 kr. Før vi siger ned mot 8-tallet i påvente av finansiell avklaring. Forventer at mye er avklart innen 4-5 mnd.
For rundt en uke siden meldte du at vi skulle se 6-tallet, hva skjedde?
I disse tider hvor vi har en del hellidager, det at staten og kirka har skilt lag plutselig ikke er så nøye da alle skal ha fridagene blir jeg også troende. Troende i den form at jeg håper du får småstein i skoa og kjempestore gnagsår - det gnålet ditt er jeg drittlei.
Amen
1 Like
Fra ASCO 2021
https://meetinglibrary.asco.org/record/197068/abstract
Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.
We report on preliminary results from the phase Ib part of the ongoing study, data cut-off Feb 1st, 2021 a total of 40 patients have been enrolled
We observed clinical activity with 1 complete response, 2 confirmed partial responses and 9 stable diseases (6 confirmed), resulting in a disease control rate of 30% in highly pretreated patients throughout all DLs.
1 Like
https://meetinglibrary.asco.org/record/196423/abstract
Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.
C-144-01 is a Phase 2, open-label, multicenter study of efficacy and safety of lifileucel in patients with advanced melanoma who have progressed on anti-PD-1 therapy and BRAFi ± MEKi, if BRAF V600+.
Baseline characteristics: 3.3 mean prior therapies (100% anti-PD-1; 80% anti-CTLA-4; 23% BRAFi/MEKi), high baseline tumor burden (106 mm mean target lesion SOD), 42% liver/brain lesions, 40.9% LDH > ULN.
ORR by investigator was 36.4% (3 CR, one new CR developed at 24 mos; 21 PR). Median duration of response (mDOR) was not reached at median follow-up of 28 mos (DOR range: 2.2- 35.2 mos).
1 Like
https://meetinglibrary.asco.org/record/195985/abstract
Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004
103 pts were enrolled. Median age was 63 y, 68.0% of pts had stage M1c/M1d disease, 55.3% had LDH > ULN (20.4% ≥2 × ULN), 58.3% received ≥2 prior treatments, 94.2% received therapy for advanced disease, and 32.0% received BRAF ± MEK inhibition. With median study follow-up of 15.3 mo (range 12.1-19.0), 17.5% of pts were still receiving study drug
ORR by BICR remained 21.4% (95% CI 13.9-30.5), although the number of CRs increased from 2 to 3. DCR was 66.0%. Median DOR increased to 8.2 mo, and the KM estimate of DOR ≥9 mo was 37.2%. ORR was 33.3% in pts with PD on prior anti–PD-1 + anti–CTLA-4 (n = 30), 18.2% in pts whose only prior anti–PD-1/L1 was in the adjuvant setting (n = 11), 22.6% in pts with primary resistance (n = 62), and 22.7% in pts with secondary resistance (n = 22). Median (95% CI) PFS and OS in the total population were 4.2 mo (3.8-7.1) and 14.0 mo (95% CI 10.8-NR); 12-mo PFS and OS estimates were 17.8% and 54.5%.
2 Likes
Dette har ingenting med Ultimovacs å gjøre, men er studier som går i refraktære melanompasienter 
Synes dataene til Targovax holder seg veldig bra!
https://meetinglibrary.asco.org/record/196420/abstract
Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.
From August 2019 to May 2020, 30 MM patients (median # of lines, 2; range, 2 - 5) were enrolled. All enrolled patients were exposed to prior anti-PD-1 treatment (immediate failure, n = 23). The ORR was 30.0% (9 PRs, 10 SDs, 10 PDs), DCR 63.3%, median PFS 7.1 months (95% confidence interval (CI), 3.6-10.6), and median OS was 14.2 months (95% CI, 9.3-19.1).
4 Likes
Tok en rask runde når disse ble tilgjengelig. Trvx fremdeles best in class blant det jeg så.
Lifileucel rapporterer bra data i 1 linje melanoma også, men dette er krevende T-celle terapy og er definitivt ikke noe off the shelf vare…
3 Likes
Konkurransen spisser seg til, tilsynelatende sammenlignbare resultater som trvx, m.a.o er det nå lettere å forstå KOL’s anbefaling om at Oncos neste studie bør ha med seg aPD-1 og aCTLA på laget …
2 Likes
Ingen av de andre som har abscopal effekt som jeg kan se? Det lover veldig bra for Targovax
6 Likes
Har du rett er det svært viktig …
Du må se hvordan disse blir administrert.
Lenkene over her dreier seg mer om oral& systemisk administrasjon, kontra IT som oncos der non injected lesions forsvinner (aka systemic / “abscopal effect”)
Ja, take away etter å ha browset gjennom studiene i refraktære pasienter er jo at Targovax absolutt har noe å gjøre der.
Når kommer siste rest av data?
4 Likes
Targovax er også flinke til å gi investorene en oversikt over konkurranse bildet i presentasjonene sine
17 Likes
Hvordan er Ultimovacs sine data opp mot Targovax? Vil de kunne gjøre at Oncos blir overflødig??
Targovax behandler de som er anti- PD1 refractory. Er det dette Ultimovacs har kjørt studie på? Nei.
1 Like
Akkurat dette med forskjellen mellom Targo og Ultimo snakket de en del om på radiumpodcasten om Targo (#175). Veldig oppklarende og godt forklart.
3 Likes
(Deleted)
5 Likes